The presentation will take place at
A live webcast of the presentation will be available on the Investors section of Freeline’s website at www.freeline.life. An archived replay of the webcast be available for approximately 90 days following the presentation.
About
Freeline is a clinical-stage biotechnology company focused on developing transformative gene therapies for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is currently advancing FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Freeline is headquartered in the
Media and Investor Contact:
naomi.aoki@freeline.life
Senior Vice President, Head of Investor Relations
+ 1 617 283 4298
Source:
2023 GlobeNewswire, Inc., source